The congestive heart failure drugs market size is estimated to be USD 6,285.9 million in 2022 and is expected to witness a CAGR of 14.79% during the forecast period 2023-2033. Strong product pipeline, ageing population, and rising prevalence of disorders including obesity, diabetes, hypertension, chronic pulmonary diseases, and renal disease are projected to drive the market growth in near future. Furthermore, increase in R&D activities and availability of a number of drugs in the clinical pipeline and rising product approvals and novel product launches are other factors supporting market growth. However, lack of awareness and frequency of diagnosis of diseases including hypertension are predicted to limit market growth are expected to restrain the market growth.

Increase in R&D activities and availability of a number of drugs in the clinical pipeline is expected to propel the market growth during the projected period. For instance, the FDA approved the NDA for Cytokinetics’ drug Omecamtiv Mecarbil in February 2022. Omecamtiv Mecarbil is a selective cardiac myosin activator that is beneficial in enhancing contractility related to heart failure. Semaglutide, tirzepatide, cimlanod, CardiAMP cell therapy, Revascor (Rexlemestrocel-L), Furoscix infusor, and others are clinical trial drugs for CHF. The approval and subsequent release of such drugs during the ensuing years is anticipated to accelerate the growth.

Rising product approvals and novel product launches is predicted to fuel the market growth during the forecast period. Through product approvals and new product launches, pharmacological alternatives for the disease are currently moving in the direction of a better treatment strategy. For instance, the FDA approved Boehringer Ingelheim’s Jardiance (empagliflozin) in February 2022 to lower the risk of adult hospitalizations and cardiovascular death. Growth is being accelerated by these novel approvals and launches.

Segmentation

By Drug Class

The market is categorized into aldosterone antagonists, beta blockers, ACE inhibitors, inotropes, diuretics, angiotensin 2 receptor blockers, others. In 2022, the ACE inhibitors segment accounted for the highest revenue share due to its efficiency as individual treatment or readily available, approved combination therapies. Additionally, it is the treatment of choice for CHF patients. Vasotec, Epaned (enalapril), Zestril, Qbrelis, Prinivil (lisinopril), and captopril are some of the drugs that are part of it. Inhibitors prevent the synthesis of angiotensin-2, which lowers blood pressure and increases cardiac output without changing heart rate. This method of controlling heart failure is the most targeted. Additionally, it is projected that the approval of an expanded label for sodium-glucose co-transporter 2 (SGLT2) inhibitors for CHF will fuel the segment’s growth. For instance, Farxiga (dapagliflozin) and Jardiance (empagliflozin) both got label expansion for the treatment of CHF in May 2020 and February 2022, respectively. These SGLT2 inhibitor drugs exhibited a 35% decrease in hospitalizations and strong cardioprotective benefits in clinical studies.

By Distribution Channel

The market is divided into online pharmacies, hospital pharmacies, and retail pharmacies. In the global market, the retail pharmacies segment accounted for the largest revenue share in 2022 owing to the fact that retail pharmacies are familiar with the majority of drugs, particularly in the homecare setting as CHF disease management requires a long drug support regimen. Drugs for CHF are also prescription medications. Drugs for CHF are also prescription medications. All of these elements support the segment’s growth. The online pharmacies market is anticipated to grow at a significant CAGR during the forecast period. The ease of purchasing is encouraged by online pharmacy platforms. Additionally, companies such as Tata 1mg and Netmeds Marketplace Ltd. facilitate the purchase of medicines online in developing nations including India.

Regional Markets

In 2022, North America region accounted for the highest revenue in the congestive heart failure drugs market and is expected to maintain its dominance during the forecast period. This is attributed to region’s increasing disease burden, growing patient awareness, rising healthcare spending, and presence of significant players. Furthermore, throughout the course of the projected period, expanding new product approval is anticipated to boost industry expansion. Italy was least affected in the European region, and Germany had the greatest CHF prevalence in 2022. Over the forecast period, the Asia Pacific area is anticipated to have the greatest CAGR. This expansion is the result of both the significant presence of multinational companies in this region and the strong CHF prevalence in countries such as China, Japan, and Australia. For instance, Australia’s expected prevalence rate of CHF in 2020 ranged from 1.2% to 5.3%, primarily as a result of the country’s increasing rates of diabetes and obesity.

Competitor Insights

Some of the key players operating in the congestive heart failure drugs market are Novartis AG, Boehringer Ingelheim International GmbH, Johnson & Johnson Services, Inc., Merck & Co., Inc., Eli Lilly and Company, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Pfizer, Inc., Otsuka Pharmaceutical Co., Ltd., Amgen Inc., and Novo Nordisk A/S.

To achieve a competitive edge, these companies are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

• For instance, in February 2021, AstraZeneca reported that Forxiga (dapagliflozin), which is indicated for heart failure in individuals with or without type-2 diabetes, has received regulatory approval in the U.S., Europe, and Japan.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including drug class and distribution channel from 2022 to 2033.

Report Scope:

Segmentation: Congestive Heart Failure Drugs Market Report 2022 – 2033

Drug Class (Revenue, USD Million), 2022 – 2033

• Aldosterone Antagonists
• Beta Blockers
• ACE Inhibitors
• Inotropes
• Diuretics
• Angiotensin 2 Receptor Blockers
• Others

Distribution Channel (Revenue, USD Million), 2022 – 2033

• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA